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Abstract. Mafosfamide (4-thioethane sulfonic acid salt of
4-hydroxy-cyclophosphamide, MAF) belongs to a new
generation of the oxazaphosphorine agents. MAF is a
cyclophosphamide analog which spontaneously degrades to
4-hydroxy-cyclophosphamide. The effects of MAF on various
types of cancer cells were determined during preclinical
investigations and clinical trials. The positive results from
in vitro and in vivo anticancer studies promoted MAF to a
good candidate for phase I trials. Clinical experience with
intrathecal MAF, used for patients with neoplastic
meningitis due to leukemia, lymphoma, and solid tumors,
indicated good tolerability and efficacy. The recommended
phase II doses of intrathecally administered MAF were
determined. Clinical trials using intrathecal MAF are now
underway. To obtain a better therapeutic index, a strategy
to alternate dosing between the intraventricular and
intralumbar routes is also being tested. MAF is an attractive
agent for regional cancer therapy. The current available
knowledge on MAF as a new anticancer agent is based on a
collection of the original published studies, conference
abstracts and relevant articles.
New Oxazaphosphorine Anticancer Agents
Oxazaphosphorines represent a class of alkylating agents
widely used in the treatment of hematological malignancies
and solid tumors. Nonetheless, the clinical use of the
oxazaphosphorine drugs cyclophosphamide (CP), ifosfamide
and trofosfamide, is limited due to their toxicity to normal
cells and cancer cell resistance against their action. Recently,
a new generation of oxazaphosphorines have been developed
in order to improve the therapeutic index and increase the
effectiveness of chemotherapy (1-6). 
Mafosfamide as a New Oxazaphosphorine Agent
Mafosfamide (CAS number 88859-04-5, MAF) is one of the
novel oxazaphosphorine agents (2, 4, 5). MAF is a
preactivated cyclophosphamide analog (Figure 1). It is a
chemically stable 4-thioethane sulfonic acid salt of 4-hydroxy-
cyclophosphamide (4-HO-CP). Mafosfamide cyclohexylamine
salt and mafosfamide lysine salt (Figure 2) were synthesized
and tested in preclinical and clinical studies (6-14). 
Metabolism and Transport of MAF
In comparison with CP, MAF does not require hepatic
activation. MAF breaks down, spontaneously, to 4-HO-CP and
a thiol, mesna (2-mercaptoethanesulfonate) cyclohexylamine
or lysine salt. The released 4-OH-CP is in equilibrium with its
tautomer aldophosphamide that can be decomposed by β-
elimination to generate cytotoxic phosphoramide mustard and
acrolein (Figure 3). Therefore, MAF is directly active in
intracellular fluids and cells. 4-OH-CP, phosphoramide mustard
and acrolein can enter cells via passive diffusion and
transporter-mediated translocation (2-5, 9, 15, 16). 
Mechanisms of MAF Action on Cells
The mechanisms of MAF action on cells have not yet been
fully explained (3, 15). However, the effects of MAF are
accepted as being mainly dependent on its reactive alkylating
agents – phosphoramide mustard and acrolein. The
metabolites of cyclophosphamide also include phosphoramide
mustard and acrolein. Thus, the mechanisms of MAF action
are similar to those of CP (1, 2, 4, 17). In the case of MAF, it
has been shown that mesna, increased the therapeutic effects
without interfering in MAF anticancer activity (7).
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The reactive alkylating agents, phosphoramide mustard
and acrolein can bind covalently to a variety of molecules.
MAF metabolites can react with available groups of amino
acids, proteins and peptides, such as NH2, COOH, SH, and
with the primary phosphate, hydroxyl and amino groups of
the bases of nucleic acids. Nevertheless, the DNA binding
site is the most important. The biological effects of MAF
are generally considered to originate from damage to
cellular DNA (16, 18, 19). After MAF application, DNA
breaks were observed in lymphocytes and leukemia cells
(20, 21). The DNA molecular damage caused by reactive
alkylating agents involving bonds between atoms,
formation of cross-bridges and strand breaks, is believed to
lead to the disruption of DNA function, inhibition of cell
division and cell death (1, 18, 22, 23). Mitotic catastrophe,
a process preceding cell death (11) and programmed cell
death were triggered by MAF (Figure 4). After exposure of
hematopoietic cells to MAF, these cells underwent
apoptosis, necrosis (10, 23-25) and autophagy (25). MAF
also affected the viability and the size of leukemia cells
(12-14, 25).
MAF in Preclinical Studies
The effects of MAF on various types of cancer cells were
determined during preclinical investigations. MAF has been
found to have significant activity in vitro against leukemia
and solid tumor cell lines such as U-937, ML-1, MOLT-4,
rhabdomyosarcoma and MCF-7, and also in vivo against
several transplantable murine tumors, including P388 and
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Figure 1. Chemical structures of cyclophosphamide and mafosfamide.
Figure 2. Chemical structures of mafosfamide cyclohexylamine salt and
mafosfamide (L-lysine) salt.
Figure 3. Mafosfamide and its metabolites. 
L1210 leukemia, B16 melanoma, Lewis lung carcinoma,
colon 38 tumor, and cyclophosphamide-resistant P388
leukemia. MAF has demonstrated anticancer activity similar
to or better than CP in mouse models and in a
cyclophosphamide-resistant P388 subline (2-5, 11, 13-15,
21, 26-28). 
The in vitro combined action of MAF with various
chemotherapeutic agents, was studied. The in vitro drug
interactions were analyzed in acute lymphoblastic leukemia
samples of children, obtained during the initial diagnosis. The
combination of prednisolone and MAF generally showed
additive and even synergistic interaction (29). The cytotoxic
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Figure 4. Morphology of human histiocytic lymphoma U-937 cells undergoing autophagy (A, B, short arrow), mitotic catastrophe (B, C, E, F, arrow
head) and necrosis (D, E, long arrow) after their exposure to the action of mafosfamide cyclohexylamine salt. U-937 cells visible under a light
microscope (A, B, C – magnification ×400; D, E, F – magnification ×1000).
combination of loxoribine with fludarabine and MAF on
freshly isolated B-chronic lymphocytic leukemia cells was
also tested. The combination of fludarabine and MAF was
synergistic towards CLL cells, and the cytotoxic activity was
increased by the addition of loxoribine (30). The cytotoxic
effects of the in vitro combined action of karenitecin and MAF
against leukemia, medulloblastoma and neuroblastoma cell
lines, were also determined (28). These investigations provide
important support for the development of the karenitecin and
mafosfamide combination for use in intrathecal therapy. 
Toxicological investigations carried out on rodents
revealed that MAF given intravenously was more toxic in
rats than in mice. The toxic LD50 lethal dose for
mafosfamide was determined to be between 500 and 625
mg/kg in mice and between 250 and 310 mg/kg in rats, after
intravenous administration. These values were much higher
than the corresponding ones for 4-OH-CP. Moreover, in a
single intravenous injection of CP (Endoxan), the LD50 was
about 160 mg/kg in the rat, and 400 mg/kg in the mouse
(31). MAF was clearly less toxic with respect to the bone
marrow, the immune system and the urinary tract. However,
the predominant toxicity in rodents was myelosuppression.
When comparing equimolar doses, it was found that myelo-
and urotoxicity caused by MAF were less severe than with
CP (5, 8, 9, 32). Because of these marked differences in
cytotoxicity, a phase I trial with MAF was warranted. 
The development of animal models of neoplastic
meningitis has been reported (33-35). The usefulness of the
athymic rat model of human neoplastic meningitis was shown
by Fuchs et al. (34). The activity and efficacy of intrathecal 4-
hydroperoxy-CP against the human rhabdomyosarcoma cell
line TE-671 and the human glioma cell line D-54 MG, grown
in the subarachnoid space of athymic rats and the lack of
toxicity at therapeutic levels of 4-hydro-peroxy-CP in normal
athymic rats were demonstrated. Preclinical studies using a
non-human primate model were also carried out (15, 33, 36,
37). The Rhesus monkey (Macaca mulatta) model of
neoplastic meningitis, using MAF, was described. Application
of a silicone catheter, surgically placed into the fourth
ventricle, and attached to a subcutaneously implanted
Ommaya reservoir, allowed for the determination of the acute
and cumulative toxicity of mafosfamide (15, 33, 36). It has
been demonstrated that MAF was well tolerated, when
applied intrathecally in Macaca mulatta. The preclinical
pharmacological studies based on the Rhesus monkey model
of neoplastic meningitis showed that intrathecal mafosfamide
administration was safe, and no systemic, nor neurologic
toxic effects were observed (2, 15, 33, 36, 37). 
MAF in Clinical Trials
The effects of mafosfamide were determined during several
phase I clinical trials. The action of MAF was analyzed in
patients with leukemia, lymphoma and central nervous system
tumors, as well as in children younger than 3 years old who
had newly diagnosed embryonal tumors. Systemic
administration of MAF by an intravenous route and regional
administration by intrathecal, intralumbar, and intraventricular
routes were tested (2-5, 8, 9, 15, 38, 39). 
Systemic intravenous administration of MAF. Mafosfamide
cyclohexylamine salt (ASTA-Z-7557) was chosen for phase
I clinical testing because of an expected higher therapeutic
index and lack of complete cross resistance in animal
tumors, compared to those observed after CP application.
ASTA-Z-7557 was given to patients with histologically
proven malignancies which either had become resistant to
standard chemotherapy or were known to be highly resistant
to cytotoxic drugs. The patients were also not eligible for
surgery or radiotherapy. The schedule consisted of a single
intravenous dose, repeated every three weeks. The maximum
tolerated dose was approximately 1000 mg/m2, given as a
slow infusion over 2-3 h. Severe pain along the injected vein
and acute irritation of mucous membranes were found to
cause ASTA-Z-7557 dose-limiting toxicity. The severe
venous pain and the mucosal irritation were probably caused
by the high local concentration of 4-OH-CP or by its
metabolites. Hematological toxicity was mild. A limited
phase I study with the lysine salt of MAF (ASTA-Z-7654)
demonstrated an identical type of toxicity. MAF given in a
high-dose intermittent schedule was of little interest for
further clinical trials (8). 
A phase I trial with cyclohexylamine and lysine salts of
MAF was also carried out on patients with advanced
malignancies which were not amenable to standard
treatments. An intravenous MAF infusion was administered
weekly for at least 5 min at doses of 200 mg/m2, 400 mg/m2
and 700 mg/m2. A dose of 700 mg/m2 per week represents
the maximum tolerated dose on a weekly schedule. Dose-
limiting toxicities were observed in the form of severe pain
along the vein during administration. After application of
cyclohexylamine salt of MAF, moderate anemia was noted
at all dose levels tested. Hematological toxicity was not
encountered with the lysine salt applied at these dose levels.
A particular mucosal syndrome with sneezing and
conjunctivitis was seen only after the administration of the
lysine salt. These results confirmed that systemic
administration of MAF by the intravenous route was
unacceptable in patients of phase I trials due to severe local
pain at the injection site (9). 
Regional intrathecal administration of MAF. The simple and
rapid hydrolysis of MAF in biological fluids made this
alkylating agent a suitable candidate for regional use. During
the phase I clinical trials, MAF was selected and tested as a
potential candidate agent for intrathecal dosing (4, 5, 15, 39). 
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A phase I clinical study assessed the effects of the
intrathecal MAF in patients with refractory neoplastic
meningitis who were treated with five doses ranging from
1.0 mg to 6.5 mg. Most of the patients had leukemia and
lymphoma neoplastic meningitis. MAF demonstrated good
activity. Chemotherapy was generally well-tolerated and
there were no reported drug-related adverse events at lower
doses. In this phase I clinical trial, headache was the dose-
limiting toxicity. Most patients experienced headaches,
probably related to the fast rate of drug infusion, associated
with the 5 mg dose. Headache was ameliorated at 5 mg by
prolonging the infusion rate to 20 min, but the dose-
limiting headache occurred at a 6.5 mg dose with prolonged
infusion. Thus, the final recommended phase II dose for
intrathecal MAF, administered without concomitant
analgesia, was 5 mg with a constant infusion rate of over
20 min (15, 37, 40). 
Another phase I trial was carried out using intrathecal
MAF in combination with multiagent systemic chemotherapy
for children younger than 3 years old, who had newly
diagnosed embryonal tumors of the central nervous system.
Patients received intrathecal MAF at one of the six dose
levels ranging from 5 to 17 mg. Patients were also
premedicated with dexamethasone at 0.15 mg/kg and
morphine at 0.1 mg/kg before receiving intrathecal MAF
dosing. Irritability, presumably secondary to pain or
headache, observed during the administration of MAF was
the dose-limiting toxicity in patients at the 17 mg dose level.
In these patients, the maximum-tolerated and recommended
phase II dose of intrathecal MAF, following premedication
with dexamethasone and morphine was establish to be 14 mg
(3, 37, 39).
Regional intraventricular and intralumbar administration of
MAF. During the phase I clinical trials, a strategy to alternate
dosing between the intraventricular and intralumbar routes
was tested. The cytotoxic target exposure for mafosfamide
was determined to be 10 μmol/l. The results of
pharmacokinetic investigations performed in patients with
Ommaya reservoirs indicated that ventricular cerebrospinal
fluid (CSF) MAF concentrations at 5 mg dosing, exceeded
the target cytotoxic concentrations after an intraventricular
dose, but lumbar CSF concentrations 2 h after the dose were
less than 10 μmol/l (3, 15). The results of these clinical
studies indicated that MAF dosing should be alternated
between the ventricular and lumbar space. 
Further Development of MAF
Mafosfamide was developed by Baxter-Oncology
(www.baxter-oncology.com). Clinical studies using MAF are
among the most recent clinical trials performed and
described in the current literature (41-43). During phase I
clinical trials, MAF appeared to be an excellent candidate for
regional administration. The recommended phase II doses of
MAF were determined (15, 39). However, the mode of MAF
action is still under experimental and clinical investigation.
Opportunity to improve mafosfamide efficacy. Elucidating the
action mechanisms of MAF on pathological and normal cells
is important for its optional use in cancer therapy. For this
reason, the response of various types of cells to the action of
this oxazaphosphorine agent should be analyzed in further
preclinical and clinical investigations. 
Current and future clinical research should focus on
methods allowing for the most effective delivery of MAF into
the CSF, in which an appropriate concentration of this agent
is maintained for extended periods. The combined
intraventricular and intralumbar routes of MAF administration
should be taken into consideration. During further clinical
trials, the ventriculolumbar cerebrospinal application
technique, using MAF, should be described in detail. A better
understanding of the pharmacokinetics and the CSF
pharmacology of MAF and of other chemotherapeutic agents
used regionally, in combination with MAF, is an essential
prerequisite for safe, effective administration of these drugs.
Investigational efforts are underway to verify the feasibility
and efficacy of MAF application at different dosages,
schedules and combinations with both other intra-CSF agents
and drugs used in systemic therapy (44-46). 
Potential of MAF for therapy of neoplastic meningitis.
Neoplastic meningitis is a problem in neuro-oncology.
Nowadays, because of new diagnostic methods introduced
into everyday clinical practice, the occurrence of
leptomeningal carcinomatosis has been noted in
approximately 5% of patients with cancer. Neoplastic
meningitis results from the leptomeningeal dissemination of
a variety of cancer types. Pathological cells spread in the
leptomeninges and the CSF. Leukemia and lymphoma, lung
and breast cancer, melanoma, and brain tumor, are the
primary diseases commonly associated with leptomeningeal
carcinomatosis. In general, the survival period of most
patients with neoplastic meningitis is short and averages only
3 to 4 months (5, 36, 43, 47-51). 
New and more effective agents, without severe local
neurotoxicity, are needed for the management of
leptomeningeal metastases. The development of new regional
agents for the treatment of neoplastic meningitis is extremely
challenging because of the limited number of drugs currently
available and the increasing frequency of patients with
neoplastic meningitis (37, 40, 43, 52, 53). 
MAF may be potentially utilized for regional
chemotherapy in the treatment of neoplastic meningitis
(www.baxter-oncology.com). MAF is believed to be a potent
candidate agent for this therapy because its mechanisms of
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action differ from those of most available intrathecal drugs
that are primarily antimetabolites. Clinical experience with
MAF in neoplastic meningitis from leukemia, lymphoma and
solid tumors indicated good tolerability and efficacy.
Combined MAF application along with the currently used
drugs could improve the therapeutic index of the treatment
of neoplastic meningitis (2, 15, 45, 50, 51).
Conclusion
Mafosfamide represents an attractive new agent for cancer
therapy. An assessment of the anticancer potential of MAF
against various types of pathological cells is of key
importance in chemotherapy. Further development of MAF
is very important for its optional use in regional cancer
therapy, and especially in the treatment of neoplastic
meningitis. 
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